Valneva SE, a prophylactic vaccine for infectious diseases developer, has filed Amendment No 3 to Form F-1 Registration Statement on April 29, 2021 with the U.S. Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $100 million by offering 3.5 million shares at a price of $28.24 Assuming a successful IPO at the midpoint of the proposed price, the company expects a market capitalization of $1.5 billion.
The company is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. They targeted an approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options.
The Saint-Herblain, France-based company was founded in 1999 and booked $131 million in sales for the 12 months ended December 31, 2020. It plans to list on the Nasdaq Global Market under the symbol “VALN.” Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co are underwriters of the IPO.
The company engages Cooley LLP as US Securities Counsel, and PricewaterhouseCoopers LLP as Independent Auditor.
#ipo #Nasdaq #vaccine #infection #Valneva
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected]
